| A Study of DS-3939a in Participants With Solid Tumors (NCT07739966) | Daiichi Sankyo | 2026-10-01 |
| T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd (NCT07683754) | Daiichi Sankyo | 2026-09-04 |
| First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors (NCT07681882) | Daiichi Sankyo | 2026-08-06 |
| A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer (NCT07701941) | Daiichi Sankyo | 2026-08-03 |
| A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia (NCT07206472) | Daiichi Sankyo | 2026-03-03 |
| A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies (NCT07220616) | Daiichi Sankyo | 2026-01-16 |
| Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin (NCT07268625) | Daiichi Sankyo | 2025-12-09 |
| A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) (NCT07244341) | Daiichi Sankyo | 2025-12-03 |
| A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer (NCT07189403) | Daiichi Sankyo | 2025-11-04 |
| A Study Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin (NCT07235189) | Daiichi Sankyo | 2025-10-28 |
| Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer (NCT06899126) | Daiichi Sankyo | 2025-10-24 |
| A Study of DS3610a in Participants With Advanced Solid Tumor (NCT07159126) | Daiichi Sankyo | 2025-10-09 |
| Evaluating Bioequivalence of a Fixed Dose Combination Versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin (NCT07201545) | Daiichi Sankyo | 2025-10-07 |
| A Study of DS5361b in Participants With Advanced Solid Tumors (NCT07182591) | Daiichi Sankyo | 2025-10-02 |
| Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer (NCT07022483) | Daiichi Sankyo | 2025-09-30 |
| Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin (NCT07182383) | Daiichi Sankyo | 2025-09-29 |
| Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (NCT07129993) | Daiichi Sankyo | 2025-09-26 |
| Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (NCT07092254) | Daiichi Sankyo | 2025-09-01 |
| A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors (NCT07015697) | Daiichi Sankyo | 2025-07-17 |
| Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i (NCT06975371) | Daiichi Sankyo | 2025-04-14 |
| A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan (NCT06925100) | Daiichi Sankyo | 2025-04-01 |
| A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) (NCT06644781) | Daiichi Sankyo | 2025-03-27 |
| Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) (NCT06819007) | Daiichi Sankyo | 2025-03-19 |
| Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer (NCT06731478) | Daiichi Sankyo | 2025-02-27 |
| Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China (NCT06846996) | Daiichi Sankyo | 2025-02-27 |
| Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan (NCT06833268) | Daiichi Sankyo | 2025-01-20 |
| A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) (NCT06660654) | Daiichi Sankyo | 2025-01-06 |
| Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML (NCT06578247) | Daiichi Sankyo | 2024-11-19 |
| First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors (NCT06644755) | Daiichi Sankyo | 2024-11-14 |
| A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations (NCT06644768) | Daiichi Sankyo | 2024-10-30 |
| Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects (NCT06740825) | Daiichi Sankyo | 2024-10-29 |
| A Study to Evaluate QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart Rate (NCT06772246) | Daiichi Sankyo | 2024-10-24 |
| Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment (NCT06740799) | Daiichi Sankyo | 2024-09-30 |
| Real-World Pharmacological Treatment Pattern of Neuropathic Pain in China (NCT06546202) | Daiichi Sankyo | 2024-08-16 |
| A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line Treatments (NCT06617390) | Daiichi Sankyo | 2024-08-15 |
| A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) (NCT06362252) | Daiichi Sankyo | 2024-07-22 |
| A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer (NCT06686602) | Daiichi Sankyo | 2024-07-09 |
| A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) (NCT06330064) | Daiichi Sankyo | 2024-04-10 |
| Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment (NCT06557967) | Daiichi Sankyo | 2024-03-01 |
| A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT06161025) | Daiichi Sankyo | 2024-02-27 |
| A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors (NCT06172478) | Daiichi Sankyo | 2024-02-26 |
| A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors (NCT06244485) | Daiichi Sankyo | 2024-02-16 |
| A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH) (NCT06210776) | Daiichi Sankyo | 2024-01-15 |
| A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) (NCT06174987) | Daiichi Sankyo | 2024-01-05 |
| Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer (NCT05950945) | Daiichi Sankyo | 2023-12-30 |
| A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome (NCT05979831) | Daiichi Sankyo | 2023-09-28 |
| First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors (NCT05875168) | Daiichi Sankyo | 2023-08-18 |
| Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer (NCT06040593) | Daiichi Sankyo | 2023-07-31 |
| A Study of DS-7011a in Patients With Systemic Lupus Erythematosus (NCT05638802) | Daiichi Sankyo | 2023-06-07 |
| A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors (NCT05765851) | Daiichi Sankyo | 2023-05-30 |
| A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer (NCT05769751) | Daiichi Sankyo | 2023-03-15 |
| A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation (NCT05804747) | Daiichi Sankyo | 2023-02-16 |
| Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) (NCT05555732) | Daiichi Sankyo | 2023-01-11 |
| EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan (NCT05458401) | Daiichi Sankyo | 2022-11-11 |
| A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum (NCT05569252) | Daiichi Sankyo | 2022-10-20 |
| A Dose Finding Study of VN-0200 (NCT05547087) | Daiichi Sankyo | 2022-10-13 |
| HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy (NCT05338970) | Daiichi Sankyo | 2022-07-08 |
| A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects (NCT05388903) | Daiichi Sankyo | 2022-06-20 |
| A Study of DS-9606a in Patients With Advanced Solid Tumors (NCT05394675) | Daiichi Sankyo | 2022-05-31 |
| Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (NCT05280470) | Daiichi Sankyo | 2022-03-09 |
| Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings (NCT05025722) | Daiichi Sankyo | 2021-08-30 |
| An Observational Study Investigating the Change in Blood Cholesterol With Mevalotin® Tablet Administration in Korean Menopausal Women Aged 50 Years or More Who Require Treatment of Dyslipidemia (NCT05120895) | Daiichi Sankyo | 2021-08-10 |
| HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer (NCT04676477) | Daiichi Sankyo | 2021-06-11 |
| Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) (NCT04703192) | Daiichi Sankyo | 2021-06-03 |
| Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) (NCT04704934) | Daiichi Sankyo | 2021-05-21 |
| A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects (NCT04796831) | Daiichi Sankyo | 2021-04-26 |
| Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (NCT04644237) | Daiichi Sankyo | 2021-03-19 |
| HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NCT04619004) | Daiichi Sankyo | 2021-02-02 |
| A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment (NCT04635111) | Daiichi Sankyo | 2021-01-07 |
| A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors (NCT04707248) | Daiichi Sankyo | 2020-12-22 |
| Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) (NCT04656652) | Daiichi Sankyo | 2020-12-21 |
| A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) (NCT04622319) | Daiichi Sankyo | 2020-12-04 |
| Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib (NCT04526704) | Daiichi Sankyo | 2020-10-20 |
| A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors (NCT04419532) | Daiichi Sankyo | 2020-10-09 |
| Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) (NCT04526691) | Daiichi Sankyo | 2020-09-15 |
| A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer (NCT04479436) | Daiichi Sankyo | 2020-09-14 |
| Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (NCT04519944) | Daiichi Sankyo | 2020-06-30 |
| DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST) (NCT04276415) | Daiichi Sankyo | 2020-05-08 |
| DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer (NCT04042701) | Daiichi Sankyo | 2020-02-10 |
| Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants (NCT04223635) | Daiichi Sankyo | 2020-01-07 |
| DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02) (NCT04014075) | Daiichi Sankyo | 2019-11-26 |
| Study of Single-dose DS-3201b in Participants With Hepatic Impairment (NCT04276662) | Daiichi Sankyo | 2019-11-21 |
| Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors (NCT04145622) | Daiichi Sankyo | 2019-11-03 |
| DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer (NCT03255083) | Daiichi Sankyo | 2019-04-10 |
| Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] (NCT03734029) | Daiichi Sankyo | 2018-12-27 |
| Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML) (NCT03552029) | Daiichi Sankyo | 2018-12-12 |
| Food Effects on Milademetan Pharmacokinetics in Healthy Participants (NCT03647202) | Daiichi Sankyo | 2018-08-16 |
| Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood (NCT03793478) | Daiichi Sankyo | 2018-08-15 |
| DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] (NCT03529110) | Daiichi Sankyo | 2018-08-09 |
| Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer (NCT03523572) | Daiichi Sankyo | 2018-08-02 |
| DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] (NCT03523585) | Daiichi Sankyo | 2018-08-01 |
| DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer (NCT03505710) | Daiichi Sankyo | 2018-05-21 |
| Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease (NCT03395639) | Daiichi Sankyo | 2018-05-15 |
| Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics) (NCT03291288) | Daiichi Sankyo | 2018-02-26 |
| DS-9231 in Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE) (NCT03316729) | Daiichi Sankyo | 2018-01-01 |
| U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer (NCT03260491) | Daiichi Sankyo | 2017-10-30 |
| Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB) (NCT04033094) | Daiichi Sankyo | 2017-10-16 |